Literature DB >> 26084261

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography.

Constantin Lapa1, Rudolf A Werner2, Ken Herrmann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26084261     DOI： 10.1007/s12020-015-0661-3

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  4 in total

1.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

2.  Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?

Authors:  Duygu Has Simsek; Serkan Kuyumcu; Cuneyt Turkmen; Yasemin Sanlı; Faruk Aykan; Seher Unal; Isik Adalet
Journal:  J Nucl Med       Date:  2014-10-14       Impact factor: 10.057

3.  Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging.

Authors:  Ronan Abgral; Sophie Leboulleux; Désirée Déandreis; Anne Aupérin; Jean Lumbroso; Clarisse Dromain; Pierre Duvillard; Dominique Elias; Thierry de Baere; Joël Guigay; Michel Ducreux; Martin Schlumberger; Eric Baudin
Journal:  J Clin Endocrinol Metab       Date:  2010-12-30       Impact factor: 5.958

4.  Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.

Authors:  Samer Ezziddin; Linda Adler; Amir Sabet; Thorsten Dirk Pöppel; Florian Grabellus; Ali Yüce; Hans-Peter Fischer; Birgit Simon; Tobias Höller; Hans-Jürgen Biersack; James Nagarajah
Journal:  J Nucl Med       Date:  2014-05-29       Impact factor: 10.057
  4 in total
  5 in total

1.  Intraindividual tumor heterogeneity in NET - Further insight by C-X-C motif chemokine receptor 4-directed imaging.

Authors:  Rudolf A Werner; Alexander Weich; Andreas Schirbel; Samuel Samnick; Andreas K Buck; Takahiro Higuchi; Hans-Jürgen Wester; Constantin Lapa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-09       Impact factor: 9.236

Review 2.  Single-cell approaches for molecular classification of endocrine tumors.

Authors:  James Koh; Nancy L Allbritton; Julie A Sosa
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

3.  Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.

Authors:  Aura D Herrera-Martínez; Manuel D Gahete; Sergio Pedraza-Arevalo; Rafael Sánchez-Sánchez; Rosa Ortega-Salas; Raquel Serrano-Blanch; Raúl M Luque; María A Gálvez-Moreno; Justo P Castaño
Journal:  Endocrine       Date:  2017-12-01       Impact factor: 3.633

4.  Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

Authors:  Rudolf A Werner; Constantin Lapa; Harun Ilhan; Takahiro Higuchi; Andreas K Buck; Sebastian Lehner; Peter Bartenstein; Frank Bengel; Imke Schatka; Dirk O Muegge; László Papp; Norbert Zsótér; Tobias Große-Ophoff; Markus Essler; Ralph A Bundschuh
Journal:  Oncotarget       Date:  2017-01-24

Review 5.  Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Sara Sheikhbahaei; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  Ann Nucl Med       Date:  2018-08-14       Impact factor: 2.668
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.